Clinical trials
Moderately to Severely Active Ulcerative Colitis clinical trials
Below are recruiting moderately to severely active ulcerative colitis clinical trials, each written for real people, not researchers. We’re tracking 102 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT05456893Recruiting
Testing blood and stool markers in active ulcerative colitis treatments
This study checks biomarkers (signals in blood and/or stool) in adults with moderate-to-severe ulcerative colitis. It compares patients starting targeted medicines and looks for marker patterns that may reflect how the disease is behaving.
Nancy, LorraineAges 18 years+ - NCT05076175RecruitingPhase 2/Phase 3
Oral ozanimod for children with moderate to severe ulcerative colitis
This trial tests whether an oral medicine called ozanimod can improve ulcerative colitis (UC) in children whose disease is moderate to severe. It’s meant for kids who didn’t fully respond—or couldn’t tolerate—standard UC treatments.
Phoenix, ArizonaAges 2–17 - NCT04999228RecruitingPhase 4
Top-down versus step-up treatment for pediatric ulcerative colitis
This trial compares two treatment approaches for children newly diagnosed with ulcerative colitis: starting with stronger medicines right away versus beginning simpler and stepping up if needed. It may help your child learn which strategy controls symptoms better with fewer flare-ups.
Shanghai, Shanghai MunicipalityAges 6–18 - NCT04314375RecruitingPhase 4
Budesonide tablets for children with mild to moderate ulcerative colitis
This trial studies whether budesonide extended-release tablets are safe and effective for improving symptoms in children ages 5–17 with active, mild to moderate ulcerative colitis. It also measures how the medicine moves through the body.
Garden Grove, CaliforniaAges 5–17 - NCT03804931RecruitingPhase 2/Phase 3
Stool transplant for moderate to severe ulcerative colitis
This trial tests whether transplanting stool bacteria into the colon (fecal microbiota transplantation) can improve ulcerative colitis symptoms in people with active, moderate to severe disease. If you qualify, the study team will also check that it’s safe for you and that you can safely undergo a scope exam.
Guangzhou, GuangdongAges 18–65 - NCT07442045Recruiting
Comparing combined vs single drug for ulcerative colitis
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
Foshan, GuangdongAges 18 years+ - NCT07686081RecruitingPhase 3
Testing ponesimod for moderate to severe ulcerative colitis
This trial tests an oral medication called ponesimod for people with ulcerative colitis that hasn't responded well to other treatments. It aims to see if ponesimod can reduce inflammation and improve symptoms.
Chula Vista, CaliforniaAges 18–75 - NCT07726888Recruiting
Guselkumab for moderate-to-severe ulcerative colitis
This study tests a drug called Guselkumab (already approved for other conditions) for treating moderate to severe ulcerative colitis. It aims to see how safe and effective the drug is in real-world patients who have not had success with other treatments.
Wenzhou, ZhejiangAges 18 years+ - NCT07470879RecruitingPhase 2
Etrasimod for Children with Ulcerative Colitis
This trial tests if the medicine etrasimod can help children with moderate to severe ulcerative colitis. You may still be able to join even if you are already taking other treatments for your condition.
New York, New YorkAges 2–11 - NCT07697456RecruitingPhase 2
Study of advanced therapies for Crohn's or ulcerative colitis
This study tests advanced treatments for people with moderate to severe Crohn's disease or ulcerative colitis who haven't responded to at least one previous therapy. It aims to find better options for managing these conditions.
Dothan, AlabamaAges 18–75 - NCT07577856RecruitingPhase 3
Testing JNJ-78934804 for moderate to severe ulcerative colitis
This study tests a new drug called JNJ-78934804 to treat ulcerative colitis (inflammation of the colon and rectum) that is moderate to severe and hasn't responded well to standard treatments. The goal is to see if this drug can reduce inflammation and improve symptoms.
Anaheim, CaliforniaAges 18 years+ - NCT07609810Recruiting
Palmitoylethanolamide for ulcerative colitis
This study tests whether adding palmitoylethanolamide (a natural compound that may help reduce inflammation) to standard treatment can improve symptoms for people with active mild-to-moderate ulcerative colitis who are not responding well to current medications.
Cairo, El-AbbasiaAges 18–65 - NCT07665723RecruitingPhase 1
Study of afimkibart and other medicines in ulcerative colitis
This study looks at how afimkibart affects the way your body processes certain other medicines. It is for people with moderate to severe ulcerative colitis and helps researchers understand how to use this treatment safely.
Chula Vista, CaliforniaAges 18–60 - NCT07513181RecruitingPhase 2
Testing ATH-063 for Hard-to-Treat Ulcerative Colitis
This study tests a new drug called ATH-063 to see if it can help people with moderate-to-severe ulcerative colitis (a condition causing inflammation and bleeding in the colon) who haven't responded well to previous biologic treatments. The goal is to find out if this new drug is safe and effective.
Miami, FloridaAges 18–75 - NCT07463183RecruitingPhase 2
Study of MK-8690 for moderate to severe ulcerative colitis
This trial tests an investigational drug called MK-8690 for people with moderate to severe ulcerative colitis (UC) who haven't responded well to other treatments or can't tolerate them. The study aims to see if the drug can help control UC symptoms safely.
Anaheim, CaliforniaAges 18–75 - NCT07845487RecruitingPhase 2
Study of PALI-2108 for moderate to severe ulcerative colitis
This trial tests an experimental drug called PALI-2108 against a placebo (a dummy treatment) for people with moderate to severe ulcerative colitis. It aims to see if PALI-2108 can help reduce symptoms and improve quality of life.
Sun City, ArizonaAges 18–75 - NCT07786389Enrolling by invitationPhase 1/Phase 2
Seaweed supplement for ulcerative colitis inflammation
This study tests whether a supplement made from seaweed (fucoidan) can help reduce gut inflammation in people with mild to moderate ulcerative colitis. If you join, you'll take the supplement and have your symptoms and blood levels checked.
Lahore, Punjab ProvinceAges 18–64 - NCT07721441Enrolling by invitation
Predicting Gut Healing in Ulcerative Colitis with a Stool Test
This study looks at whether a simple stool test can tell if treatment is healing the gut lining in people with moderate to severe ulcerative colitis who are starting their first biologic medicine. If it works, this test might help doctors adjust treatment earlier.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06095128RecruitingPhase 4
Combination therapy for ulcerative colitis
This study tests two drugs together, vedolizumab and tofacitinib, to see if they are more effective than either alone in treating moderate to severe ulcerative colitis. It may be an option if other treatments have not worked well for you.
Dothan, AlabamaAges 18–65 - NCT04183608RecruitingPhase 4
Telemonitoring and education to guide treatment for ulcerative colitis
This trial tests whether “treat-to-target” care—guided by regular symptom checks, telemonitoring, and patient education—works better than standard follow-up when starting adalimumab for ulcerative colitis. It aims to help control inflammation more effectively and reduce flare-ups.
Cholet, Maine Et LoireAges 18–75 - NCT06335160Recruiting
Mebendazole for mild to moderate ulcerative colitis
This study tests adding a medicine called mebendazole (normally used for parasites) to standard mesalamine treatment for people with mild or moderate ulcerative colitis. The goal is to see if it helps control inflammation better than mesalamine alone.
TantaAges 18–75 - NCT05987852Recruiting
Hyperbaric oxygen therapy for ulcerative colitis flare
This trial tests if hyperbaric oxygen therapy (breathing pure oxygen in a special chamber) can help people hospitalized with a moderate to severe ulcerative colitis flare get better faster. You will receive the therapy along with standard steroid treatment.
Birmingham, AlabamaAges 18–85 - NCT07341282RecruitingPhase 2
Vancomycin for ulcerative colitis with liver condition
This trial tests whether the antibiotic vancomycin can help treat active ulcerative colitis in people who also have primary sclerosing cholangitis (a liver condition). Vancomycin may reduce inflammation in the gut by changing the bacteria in your intestines.
Hamilton, OntarioAges 18 years+ - NCT06100289RecruitingPhase 3
Study of vedolizumab for kids with ulcerative colitis or Crohn's disease
This trial tests vedolizumab, a biologic medicine that reduces inflammation, in children and teenagers who have moderate to severe ulcerative colitis or Crohn's disease and have not responded well to other treatments.
Phoenix, ArizonaAges 2–17
Hear when a new Moderately to Severely Active Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for moderately to severely active ulcerative colitis?
- Yes. Clin2 currently lists 102 recruiting moderately to severely active ulcerative colitis studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a moderately to severely active ulcerative colitis trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a moderately to severely active ulcerative colitis trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.